Exploring The Historical Stigma Of Spironolactone Use In Breast Cancer Survivors With Alopecia

    April 2023 in “ International Journal of Women's Dermatology ”
    Michael G. Buontempo, Lina Alhanshali, Jerry Shapiro, Kristen Lo Sicco
    Studysummary In this review, the authors reported that past concerns linking spironolactone to an increased risk of breast cancer are unfounded, citing recent studies that confirm no such association, indicating spironolactone's potential as a treatment for alopecia in women without fear of cancer recurrence.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on journals.lww.com →
    Discuss this study in the Community →

    Research cited in this study 2

    1. Association of Spironolactone Use With Risk of Cancer: A Systematic Review and Meta-Analysis JAMA Dermatology · 2022
    2. Clinicopathologic Characteristics and Response to Treatment of Persistent Chemotherapy-Induced Alopecia in Breast Cancer Survivors JAMA Dermatology · 2021